{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:45:26Z","timestamp":1787748326520,"version":"build-2784847793"},"reference-count":25,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T00:00:00Z","timestamp":1661040000000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:p>Apolipoprotein M (apoM), primarily carried by HDL, has been associated with several conditions, including cardiovascular disease and diabetic nephropathy. This study proposes to examine whether plasma apoM levels are associated with the development of diabetic kidney disease, assessed as progression to macroalbuminuria (MA) and chronic kidney disease (CKD). Plasma apoM was measured using an enzyme immunoassay in 386 subjects from the Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) cohort at DCCT entry and closeout and the concentrations used to determine the association with risk of progression to kidney dysfunction from the time of measurement through 18 years of EDIC follow-up. apoM levels, at DCCT baseline, were higher in patients who developed CKD than in those who retained normal renal function. At DCCT closeout, participants who progressed to MA, CKD, or both MA and CKD also had significantly higher apoM levels than those who remained normal, and increased levels of apoM were associated with increased risk of progression to both MA (risk ratio [RR] 1.30 [95% CI 1.01, 1.66]) and CKD (RR 1.69 [95% CI 1.18, 2.44]). Our results strongly suggest that alterations in apoM and therefore in the composition and function of HDL in type 1 diabetes are present early in the disease process and are associated with the development of nephropathy.<\/jats:p>","DOI":"10.2337\/db21-0920","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T22:17:54Z","timestamp":1652393874000},"page":"1795-1799","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":12,"title":["Plasma apoM Levels and Progression to Kidney Dysfunction in Patients With Type 1 Diabetes"],"prefix":"10.2337","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-1579","authenticated-orcid":false,"given":"Nathaniel L.","family":"Baker","sequence":"first","affiliation":[{"name":"1Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar M.","family":"Hammad","sequence":"additional","affiliation":[{"name":"2Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Hunt","sequence":"additional","affiliation":[{"name":"1Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Semler","sequence":"additional","affiliation":[{"name":"3Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of Medicine, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Klein","sequence":"additional","affiliation":[{"name":"3Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of Medicine, Medical University of South Carolina, Charleston, SC"},{"name":"4Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5572-1700","authenticated-orcid":false,"given":"Maria F.","family":"Lopes-Virella","sequence":"additional","affiliation":[{"name":"3Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of Medicine, Medical University of South Carolina, Charleston, SC"},{"name":"4Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2022,8,21]]},"reference":[{"key":"2022072618584738600_B1","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1074\/jbc.M704576200","article-title":"Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice","volume":"283","author":"Christoffersen","year":"2008","journal-title":"J Biol Chem"},{"key":"2022072618584738600_B2","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.2337\/diabetes.52.12.2989","article-title":"Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels","volume":"52","author":"Richter","year":"2003","journal-title":"Diabetes"},{"key":"2022072618584738600_B3","doi-asserted-by":"crossref","first-page":"31286","DOI":"10.1074\/jbc.274.44.31286","article-title":"A novel human apolipoprotein (apoM)","volume":"274","author":"Xu","year":"1999","journal-title":"J Biol Chem"},{"key":"2022072618584738600_B4","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1194\/jlr.M600055-JLR200","article-title":"Isolation and characterization of human apolipoprotein M-containing lipoproteins","volume":"47","author":"Christoffersen","year":"2006","journal-title":"J Lipid Res"},{"key":"2022072618584738600_B5","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/CIRCRESAHA.109.211086","article-title":"Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis","volume":"106","author":"Christoffersen","year":"2010","journal-title":"Circ Res"},{"key":"2022072618584738600_B6","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.1103187108","article-title":"Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M","volume":"108","author":"Christoffersen","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022072618584738600_B7","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1194\/jlr.M700113-JLR200","article-title":"An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma","volume":"48","author":"Axler","year":"2007","journal-title":"J Lipid Res"},{"key":"2022072618584738600_B8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.atherosclerosis.2015.06.040","article-title":"Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration","volume":"241","author":"Denimal","year":"2015","journal-title":"Atherosclerosis"},{"key":"2022072618584738600_B9","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.3390\/ijms20246273","article-title":"Novel insights into the role of HDL-associated sphingosine-1-phosphate in cardiometabolic diseases","volume":"20","author":"Diarte-A\u00f1azco","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2022072618584738600_B10","doi-asserted-by":"crossref","first-page":"180705","DOI":"10.1155\/2012\/180705","article-title":"Sphingosine 1-phosphate distribution in human plasma: associations with lipid profiles","volume":"2012","author":"Hammad","year":"2012","journal-title":"J Lipids"},{"key":"2022072618584738600_B11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCRESAHA.107.165845","article-title":"Vascular endothelium as a contributor of plasma sphingosine 1-phosphate","volume":"102","author":"Venkataraman","year":"2008","journal-title":"Circ Res"},{"key":"2022072618584738600_B12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/bph.12174","article-title":"HDL and endothelial protection","volume":"169","author":"Tran-Dinh","year":"2013","journal-title":"Br J Pharmacol"},{"key":"2022072618584738600_B13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/cvr\/cvu136","article-title":"Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P)","volume":"103","author":"Pot\u00ec","year":"2014","journal-title":"Cardiovasc Res"},{"key":"2022072618584738600_B14","doi-asserted-by":"crossref","first-page":"665393","DOI":"10.3389\/fendo.2021.665393","article-title":"Apolipoprotein M-A marker or an active player in type II diabetes?","volume":"12","author":"Christoffersen","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2022072618584738600_B15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2796.2009.02145.x","article-title":"An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA","volume":"267","author":"Cervin","year":"2010","journal-title":"J Intern Med"},{"key":"2022072618584738600_B16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12944-016-0325-1","article-title":"Effects of hyperlipidaemia on plasma apolipoprotein M levels in patients with type 2 diabetes mellitus: an independent case-control study","volume":"15","author":"Zhang","year":"2016","journal-title":"Lipids Health Dis"},{"key":"2022072618584738600_B17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1900\/RDS.2007.4.231","article-title":"Evaluation of apolipoprotein M serum concentration as a biomarker of HNF-1alpha MODY","volume":"4","author":"Skupien","year":"2007","journal-title":"Rev Diabet Stud"},{"key":"2022072618584738600_B18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cca.2017.01.006","article-title":"ApoM\/HDL-C and apoM\/apoA-I ratios are indicators of diabetic nephropathy in healthy controls and type 2 diabetes mellitus","volume":"466","author":"Zhang","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2022072618584738600_B19","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/ATVBAHA.117.309275","article-title":"A shift in ApoM\/S1P between HDL-particles in women with type 1 diabetes mellitus is associated with impaired anti-inflammatory effects of the ApoM\/S1P complex","volume":"37","author":"Frej","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022072618584738600_B20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2337\/diab.35.5.530","article-title":"The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase","volume":"35","author":"The DCCT Research Group","year":"1986","journal-title":"Diabetes"},{"key":"2022072618584738600_B21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/diacare.22.1.99","article-title":"Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort","volume":"22","author":"Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group","year":"1999","journal-title":"Diabetes Care"},{"key":"2022072618584738600_B22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022072618584738600_B23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2022072618584738600_B24","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"2022072618584738600_B25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.mol.0000226122.10005.88","article-title":"Apolipoprotein M--a novel player in high-density lipoprotein metabolism and atherosclerosis","volume":"17","author":"Dahlb\u00e4ck","year":"2006","journal-title":"Curr Opin Lipidol"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/71\/8\/1795\/685694\/db210920.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/71\/8\/1795\/685694\/db210920.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:44:27Z","timestamp":1667407467000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/71\/8\/1795\/146945\/Plasma-apoM-Levels-and-Progression-to-Kidney"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,21]]},"published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db21-0920","relation":{},"ISSN":["0012-1797"],"issn-type":[{"value":"0012-1797","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}